Welcome to our dedicated page for Perrigo Co Plc news (Ticker: PRGO), a resource for investors and traders seeking the latest updates and insights on Perrigo Co Plc stock.
Perrigo Company plc (NYSE: PRGO) is a pure-play self-care and consumer health company whose news flow is closely tied to its over-the-counter (OTC) product portfolio, category performance and strategic initiatives. The company regularly issues updates on its Consumer Self-Care Americas and Consumer Self-Care International segments, highlighting trends in categories such as Upper Respiratory, Pain & Sleep Aids, Digestive Health, Nutrition, Vitamins, Minerals and Supplements, Women’s Health, Skin Care, Oral Care and Healthy Lifestyle.
On this page, readers can follow Perrigo’s earnings announcements, where the company discusses net sales, organic growth, segment performance and the impact of divestitures and exited products. These releases often reference store brand market share gains in OTC categories, performance of key brands and progress under its Three-S plan (Stabilize, Streamline, Strengthen). Updates on Project Energize, the global investment and efficiency program designed to support the One Perrigo growth strategy, are also a recurring theme in recent communications.
Perrigo’s news also covers portfolio actions and strategic reviews. The company has disclosed an agreement to sell its Dermacosmetics branded business in certain European markets and has announced strategic reviews of its Oral Care and infant formula businesses. In addition, readers will find announcements related to dividends, participation in investor conferences and brand-level initiatives, such as collaborations involving Opill®, which Perrigo describes as the first daily birth control pill available without a prescription in the United States.
Investors, analysts and consumers can use this news feed to monitor how Perrigo is positioning its OTC and self-care portfolio, how its store brand and branded businesses are performing across regions and categories, and how management is adjusting the company’s structure and investments in response to market conditions.
Perrigo Company plc (NYSE: PRGO) has appointed Dr. David Ball as Executive Vice President and Chief Brand and Digital Officer, a newly created position. Dr. Ball will be responsible for developing an enterprise-wide marketing strategy focusing on consumer needs and brand-building efforts. He brings over 15 years of global consumer goods experience from roles at Bayer Consumer Healthcare and Procter & Gamble.
Dr. Ball's appointment is expected to strengthen Perrigo's global over-the-counter business and support its blended-branded strategy. His unique combination of consumer goods expertise and scientific background (PhD in Biophysics and Genetics) is seen as valuable for innovation and sustainable practices in the company's 135-year history.
Perrigo reported Q2 2024 financial results, with net sales of $1.1 billion, down 10.7% year-over-year. Organic net sales decreased 9.1%, primarily due to lower infant formula sales and reduced demand in Upper Respiratory and Pain & Sleep Aids categories. Adjusted diluted EPS was $0.53, compared to $0.63 in Q2 2023. The company reaffirmed its fiscal 2024 adjusted diluted EPS outlook of $2.50-$2.65, despite updating its organic net sales growth outlook to -3% to -1% from the previous +1% to +3%. Perrigo is progressing with its Project Energize efficiency program, targeting $140-$170 million in annualized pre-tax savings by 2026. The company completed the divestment of its HRA Pharma Rare Diseases business on July 10, 2024.
Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, has announced a quarterly dividend of $0.276 per share. The dividend is payable on September 17, 2024, to shareholders of record on August 30, 2024. Perrigo is a prominent provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions, focusing on empowering consumers to prevent or treat self-manageable conditions.
Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference. President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to present on Wednesday, August 14 at 3:30 PM EDT.
Interested parties can access the webcast on the Perrigo website at http://perrigo.investorroom.com/events-webcasts. Perrigo is known for offering over-the-counter (OTC) health and wellness solutions that empower consumers to proactively prevent or treat self-manageable conditions, enhancing individual well-being.
Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, has announced its plan to release second quarter 2024 financial results on Friday, August 2, 2024. The company will host a conference call at 8:30 A.M. (EST) on the same day. Interested parties can access the earnings conference call via webcast on Perrigo's investor relations website or by phone. A taped replay of the call will be available from approximately 12:00 P.M. (EST) on August 2 until midnight on August 9, 2024.
Perrigo specializes in over-the-counter (OTC) health and wellness solutions, focusing on empowering consumers to proactively prevent or treat self-manageable conditions.
Perrigo Company plc (NYSE PRGO), a leader in Consumer Self-Care Products, has finalized the sale of its HRA Pharma Rare Diseases business to Esteve Healthcare for a total of up to €275 million. The deal includes an upfront cash payment of €190 million with adjustments, and potential earnout payments of up to €85 million based on sales milestones. Proceeds are expected to be used for debt repayment. In 2023, the divested business generated €50 million in net sales and €20 million in adjusted EBITDA. This transaction was anticipated in Perrigo's 2024 financial outlook.
Perrigo Company (NYSE: PRGO), a leader in Consumer Self-Care Products, announced that its President and CEO, Patrick Lockwood-Taylor, along with CFO Eduardo Bezerra, will present at the Oppenheimer 24th Annual Consumer Growth & E-Commerce Conference. The event is scheduled to be held virtually on June 11, 2024, at 1:30 PM EDT. The presentation will be accessible via a webcast on Perrigo's investor relations webpage.
Perrigo reported first quarter 2024 financial results with adjusted diluted earnings per share above projections due to infant formula shipments. The company reaffirmed its 2024 financial outlook and highlighted progress in building One Perrigo. However, first quarter net sales declined 8.4%, with organic net sales decreasing 7.0%, primarily from lower infant formula sales and SKU prioritization actions. Gross margin declined, and adjusted EPS decreased by 35.6%. The company launched Opill®, the first over-the-counter birth control pill in the US. Perrigo also announced the divestment of its HRA Rare Diseases Business. Project Energize aims to drive growth and efficiency, expecting $140-$170 million in annual savings by 2026. An executive transition was announced for the Consumer Self-Care International Business. Cash equivalents were $659 million, and the company maintained its fiscal year 2024 outlook.
Perrigo Company plc announced an executive transition within its Consumer Self-Care International (CSCI) Business. Svend Andersen, EVP and President of CSCI, will retire in December, with Roberto Khoury taking over. Khoury, a seasoned consumer health professional, will bring his vast experience to lead the CSCI segment. Andersen will work alongside Khoury until August for a smooth handover. Khoury's background includes leadership roles at Kenvue and L'Oréal, emphasizing his expertise in the consumer products industry.
Perrigo Company plc (NYSE: PRGO) declared a quarterly dividend of $0.276 per share, payable on June 18, 2024, to shareholders of record on May 31, 2024. Perrigo is a global provider of Consumer Self-Care Products and OTC health solutions.